Medication info

Anewbia 50 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Kujoo Pharmaceutical Co., Ltd.
Appearance
Yellow-orange, round, biconvex film-coated tablet
Packaging
28 tablets) 14 tablets/PTP (x2), 30 tablets) 10 tablets/PTP (x3)
Approval status
Expired

MFDS item code 202004031 · Approved 2020.05.29

This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken without regard to meals. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). Administer 50 mg once daily in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). Administer 25 mg once daily in patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Ingredients

Manufacturer
Kujoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in controlling blood sugar in patients with type 2 diabetes
View approved original text

This medication is used together with diet and exercise to help control blood sugar in patients with type 2 diabetes. It can be administered alone, and if adequate blood sugar control is difficult with monotherapy for treatment-naive patients, it may be combined with metformin. Additionally, when blood sugar control is not achieved with monotherapy using sulfonylurea, metformin, thiazolidinediones, or insulin, this medication can be used in combination for treatment. This drug helps improve blood sugar control in various settings.

How to take

Adult dose

This medicine is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken without regard to meals. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). Administer 50 mg once daily in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). Administer 25 mg once daily in patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Precautions

This medication may cause serious allergic reactions, so if symptoms such as skin rash or difficulty breathing occur, stop taking it immediately and consult a healthcare professional. While taking this medication, pancreatitis, which is inflammation of the pancreas, may occur, so if severe abdominal pain, vomiting, or nausea arise, you should seek medical attention immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should not be administered if there is an allergy to this medication or its components. Patients with reduced kidney function need dosage adjustments, so they should have regular kidney function tests and take this medication according to their healthcare provider's instructions. Clinical trials and post-marketing surveys have reported side effects such as hypoglycemia, headaches, upper respiratory infections, dyspepsia, diarrhea, etc., so if symptoms are severe or persistent, consult a healthcare professional. Especially when taken with other blood glucose-lowering agents such as insulin or sulfonylurea, the risk of hypoglycemia increases, so blood glucose levels should be monitored closely. If joint pain worsens or blisters occur during treatment with this medication, notify your physician immediately, and discontinuation of medication may be necessary. Pregnant or breastfeeding women should avoid using this medication, and safety and efficacy have not been established in children under 18 years of age. The elderly may have reduced kidney function, so kidney function should be assessed before use and periodic evaluations should be conducted during treatment. In case of overdose, seek medical care immediately for appropriate treatment; this medication can be partially removed by hemodialysis. No significant interactions with several other medications have been reported, but patients should inform their healthcare provider when taking specific medications.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory infection
  • nasopharyngitis
  • headache
  • diarrhea
  • abdominal pain
Show 32 more
  • nausea
  • constipation
  • vomiting
  • rash
  • urticaria
  • cutaneous vasculitis
  • severe and disabling arthralgia
  • blistering-like pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased ALT
  • increased AST
  • increased serum triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container that is well-ventilated and kept at room temperature between 1 to 30 degrees Celsius. Storing it this way helps maintain the drug's effectiveness and prevents degradation.

Appearance and packaging

Appearance

Yellow-orange, round, biconvex film-coated tablet

Package unit

28 tablets) 14 tablets/PTP (x2), 30 tablets) 10 tablets/PTP (x3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.